ClinicalTrials.gg
RecruitingNCT06854003BRAZANUpdated Feb 20, 2026

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

A Phase 2 interventional study of Bendamustine and Rituximab in Mantle Cell Lymphoma and Lymphoma, sponsored by Christine Ryan. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Christine Ryan · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 157 studies testing rituximab in Lymphoma, Mantle-Cell — 12 open to participants now, 30 under way, 3 of them phase 3. Rituximab · Lymphoma, Mantle-Cell.

Planned enrollment
34th of 153
60 · median 37
Started
2025
with 3 others
Phase 2
92 of 157
9 open now
Primary completion
2029-11
later than 27 of 29 live
Registered
154th of 157
by date

Among the 157 studies testing rituximab in Lymphoma, Mantle-Cell, this one is the 34th largest by planned enrollment of the 153 interventional ones that give a count, is one of 4 that started in 2025, is one of 92 in phase 2, reaches primary completion later than 27 of the 29 other live ones, and was the 154th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

12 of the 157 studies testing rituximab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies testing rituximab in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL).

The names of the study drugs involved in this study are:

  • bendamustine (a type of alkylating agent)
  • rituximab (a type of monoclonal antibody)
  • cytarabine (a type of antineoplastic)
  • zanubrutinib (a type of kinase inhibitor)
  • sonrotoclax (a type of BCL2 inhibitor)
Read the detailed description

This Phase 2, multi-center, randomized study is to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with MCL. These specific maintenance therapy combinations are investigational and are being evaluated to see if the therapies may lengthen the time before MCL returns after initial therapy.

After completing induction therapy, participants will be randomized into one of two groups: Arm A: zanubrutinib + rituximab or Arm B: zanubrutinib + rituximab + sonrotoclax. Randomization means a participant is placed into a study group by chance.

The U.S. Food and Drug Administration (FDA) has approved bendamustine, cytarabine, rituximab, and zanubrutinib for the treatment of other lymphomas and/or blood cancers.

The FDA has approved rituximab as a treatment option for Mantle Cell Lymphoma (MCL).

The FDA has also approved zanubrutinib for mantle cell lymphoma, but only after trying other therapies first.

The FDA has not approved sonrotoclax as a treatment for Mantle Cell Lymphoma (MCL). However sonrotoclax works similarly to a drug called venetoclax, which is also sometimes used to treat mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved venetoclax for the treatment of other blood cancers.

The research study procedures include screening for eligibility, in-clinic treatment visits, electrocardiograms (ECGs), Positron Emission Tomography (PET) scans, Computerized Tomography CT) scans, blood tests, urine tests, lymph node biopsies, and bone marrow biopsies.

It is expected that about 60 people will take part in this research study.

The induction therapy will be 6 "cycles", or rounds of treatment, which will last for up to a little over 5 months. The maintenance therapy will last for up to 2 years.

  • Induction phase:

    • Bendamustine/Rituximab + Zanubrutinib for 3 cycles
    • Rituximab/Cytarabine for 3 cycles
  • Maintenance phase - either:

    • A) Zanubrutinib + Rituximab, or
    • B) Zanubrutinib + Sonrotoclax + Rituximab

BeiGene, Ltd., a pharmaceutical company, is also supporting this research study by providing the drugs zanubrutinib and sonrotoclax and other funding support.

03

Conditions studied

  • Mantle Cell Lymphoma
  • Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of mantle cell lymphoma, with review of the diagnostic pathology specimen at one of the participating institutions. Whenever possible, the Ki67 fraction should be reported or evaluated, cytogenetics should be performed, and TP53 status should be assessed (preferably by next-generation sequencing; immunohistochemical staining would be next-preferred).
  • No prior anti-lymphoma therapy, with the following exceptions:

    • Prior radiotherapy for localized disease is permitted.
    • A course of radiotherapy for urgent symptomatic disease is also permitted. Short-course systemic is permissible for disease control (must be \< 7 days and ≤ 100mg/day of prednisone or ≤ 20mg/day of dexamethasone, or equivalent). Steroids must be discontinued prior to study treatment.
  • , defined as ≥1 measurable nodal lesion (long axis >1.5 cm or short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on PET, CT, or magnetic resonance imaging (MRI). Disease should be FDG-avid based on PET.
  • (ECOG) performance status of 0-2. (Appendix A)
  • Age ≥18 years and considered a candidate for high-dose cytarabine by the treating physician.
  • Adequate hematologic and organ function defined as:

    • ≥ 1.0 x109/L, or ≥ 0.5 x109/L if bone marrow involvement (use of growth factor support allowed).
    • ≥ 8 g/dL and independent of transfusion within 7 days of screening.
    • ≥ 100 x109/L, or ≥ 50 x109/L if bone marrow involvement, and independent of transfusion within 7 days of screening.
    • Estimated ≥ 30mL/min (by Cockcroft-Gault formula or by 24-hour urine collection).
    • /ALT \< 2.5 X institutional (ULN), or \< 5.0 X institutional ULN if documented liver involvement of lymphoma.
    • Total \< 2.0 X ULN (unless active hemolysis); for subjects with Gilbert's Syndrome, direct bilirubin \< 1.5 X ULN.
  • Patients with known infection with (HIV) are eligible, provided all 3 of the following are true: 1) presence of controlled disease, defined as ≥ 200/uL and an undetectable viral load, 2) disease control has been stable on anti-retroviral therapy for at least 6 months prior to study enrollment, and 3) there are no prohibitive drug-drug interactions between study drugs and the necessary anti- retroviral therapies.
  • Willingness to provide a pre-treatment tumor sample by core needle or excisional surgical . A fresh biopsy is strongly encouraged, but an archival sample is acceptable if it is collected within 90 days and without intervening treatment and the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively-charged glass slides. Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the Sponsor-Investigator.
  • Willingness to remain abstinent or to use two effective methods that result in a failure rate of \<1% per year from screening until at least:

    • 6 months after the last dose of bendamustine,
    • 6 months after the last dose of cytarabine,
    • 90 days after the last dose of zanubrutinib,
    • 90 days after the last dose of sonrotoclax, and/or
    • 12 months after the last dose of rituximab, whichever of the above is longest. Examples of contraceptive methods with a failure rate of \<1% per year include:

      • Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
      • Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \<1% per year. Barrier methods must always be supplemented with the use of a spermicide.
      • True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. In contrast, periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system involvement.
  • Known active infection requiring systemic antimicrobial therapy at trial enrollment.
  • Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
  • Participants who require warfarin or other vitamin K antagonists for anticoagulation. Other anticoagulants including direct oral anticoagulants (i.e. apixaban, rivaroxaban) and low-molecular weight heparin are allowed.
  • History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusions or other medical interventions.
  • History of stroke or intracranial hemorrhage within 6 months of first dose of zanubrutinib.
  • History of significant or life-threatening hemorrhage within 3 months of first dose of zanubrutinib.
  • History of uncontrolled hemolytic anemia or immune thrombocytopenia, unless these conditions are related to the underlying .
  • Active infection. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable (NOTE: the limit of detection for HCV RNA must have a sensitivity of \< 15 IU/mL). Subjects who received treatment for HCV that was intended to eradicate the virus and who have an undetectable HCV RNA may participate without serial HCV RNA screening. Other patients may participate if they are willing to undergo every 3- month monitoring for HCV reactivation.
  • Active infection. Patients with positive hepatitis B serologies with undetectable HBV DNA (NOTE: the limit of detection for HBV DNA must have a sensitivity of \< 20 IU/mL) are permitted in the trial but should receive prophylactic antiviral therapy (i.e. entecavir) and undergo every 3 month HBV DNA monitoring.
  • Prior history of another malignancy unless treated with curative intent and disease-free for at least 3 years at time of screening with expected low risk of recurrence during expected timeframe of study participation. Such patients should first be discussed with the Sponsor-Investigator. Additional exceptions: non-melanoma skin cancer, in situ cervical or breast cancer, or Gleason 6 prostate cancer managed with observation.
  • Patients with the following cardiac conditions will be excluded:

    • Class III or IV heart failure.
    • Myocardial infarction within 6 months of screening.
    • Unstable angina within 3 months prior to screening.
    • Active uncontrolled arrhythmia.
    • History of ventricular arrhythmias within 6 months of screening (eg sustained Vtach, Vfib, torsades de pointes).
    • History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place.
    • Uncontrolled hypertension as indicated by ≥ 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mm Hg and diastolic blood pressure > 105 mm Hg at screening.
  • Screening 12-lead showing a baseline (Fridericia's correction) > 480 msec.
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function, such as malabsorption syndrome.
  • Participants receiving any medications or substances that are strong inducers.

Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.

  • Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study or limit adherence to study requirements.
  • Inability to comply with protocol mandated restrictions.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Induction Therapy (All Patients)

    Enrolled participants will complete: * Baseline visit with PET/CT, lymph node biopsy, and bone marrow biopsy * Cycles 1 through 3 (28-day cycles): * Days 1 - 28: Predetermined dose of Zanubrutinib 2x daily * Days 1 and 2: Predetermined dose of Bendamustine 1x daily * Day 1: Predetermined dose of Rituximab 1x daily * PET/CT scan * Cycles 4 through 6 (21-day cycles): * Day 1: Predetermined dose of Rituximab 1x daily * Days 1 and 2: Predetermined dose of Cytarabine 2x daily * PET/CT scan Participants without disease progression will proceed to randomization to either Arm A or Arm B for maintenance therapy.

    Drug: Bendamustine · Drug: Rituximab · Drug: Cytarabine · Drug: Zanubrutinib

  • Experimental
    Maintenance Arm A: Zanubrutinib + Rituximab

    Following randomization participants with a complete response to induction therapy will complete: * Cycles 1 - 24 (28-day cycles): * Days 1 through 28: Predetermined dose of Zanubrutinib 2x daily * Day 1 every other cycle: Predetermined dose of Rituximab 1x daily * PET/CT on Cycles 7, 12, 19, and at end of treatment * Post-treatment follow up: every 6 months. PET/CT every 12 months

    Drug: Rituximab · Drug: Zanubrutinib

  • Experimental
    Maintenance Arm B: Zanubrutinib + Rituximab + Sonrotoclax

    Following randomization participants with a complete response to induction therapy will complete: * Cycles 1 - 24 (28-day cycles): * Days 1 through 28: Predetermined dose of Zanubrutinib 2x daily * Days 1 through 28: Predetermined dose of Sonrotoclax 1x daily * Day 1 every other cycle: Predetermined dose of Rituximab 1x daily * PET/CT on Cycles 7, 12, 19, and at end of treatment * Post-treatment follow up: every 6 months. PET/CT every 12 months

    Drug: Rituximab · Drug: Zanubrutinib · Drug: Sonrotoclax

  • Experimental
    Maintenance Arm B with Sonrotoclax Ramp-Up: Zanubrutinib + Rituximab + Sonrotoclax

    Following randomization participants with an incomplete response to induction therapy will require a ramp-up initiation of sonrotoclax and will complete: * Cycles 1 - 24 (28-day cycles): * Days 1 through 28: Predetermined dose of Zanubrutinib 2x daily * Days 1 through 28: Predetermined dose of Sonrotoclax 1x daily \*\*Cycles 1 and 2: Predetermined dose of Sonrotoclax 1x daily will be increased weekly. * Day 1 every other cycle: Predetermined dose of Rituximab 1x daily * PET/CT on Cycles 7, 12, 19, and at end of treatment * Post-treatment follow up: every 6 months. PET/CT every 12 months

    Drug: Rituximab · Drug: Zanubrutinib · Drug: Sonrotoclax

Interventions

  • An Alkylating agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

    Also known as: Bendamustine hydrochloride, C16H21Cl2N3O2 · HCl, Bendeka

  • An Anti-CD20 antibody, single-use vials, via intravenous infusion per institutional standard of care.

    Also known as: Riabni, Rituxan, Ruxience, Truxima, ABP 798, IDEC-C2B8, PF-05280586, MabThera

  • An Antineoplastic, single dose vial via intravenous infusion per institutional standard of care.

    Also known as: AraC

  • A BTK inhibitor, capsule taken orally per protocol.

    Also known as: Brukinsa, BGB-3111, C27H29N5O3

  • A BCL 2 Protein Inhibitor, immediate release tablet, taken orally per protocol.

    Also known as: BGB-11417

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CRR) after 1-year of Maintenance Treatment

    CRR after maintenance treatment is defined as the proportion of participants who experienced complete response (CR) with peripheral blood (PB) MRD-negativity after 1-year of maintenance therapy.

    Time frame: Up to 125 weeks

Secondary outcomes

  1. Grade 4 Treatment-Related Toxicity Rate of zanubrutinib in combination with sonrotoclax and rituximab

    The percentage of participants who experienced a maximum grade 4 treatment-related adverse event based on the Common Toxicity Criteria for Adverse events Version 5.0 (CTCAEv5) as reported on case report forms.

    Time frame: Up to 125 weeks

  2. Grade 4 Treatment-Related Toxicity Rate of zanubrutinib in combination with BR

    The percentage of participants who experienced a maximum grade 4 treatment-related adverse event based on the Common Toxicity Criteria for Adverse events Version 5.0 (CTCAEv5) as reported on case report forms.

    Time frame: Up to 125 weeks

  3. Complete Response Rate (CRR) after Maintenance Treatment in doublet arm

    CRR after maintenance treatment is defined as the proportion of participants who experienced complete response (CR) with PB MRD-negativity after maintenance therapy.

    Time frame: Up to 125 weeks

  4. Complete Response Rate (CRR) after Maintenance Treatment in triplet arm

    CRR after maintenance treatment is defined as the proportion of participants who experienced complete response (CR) with PB MRD-negativity after maintenance therapy.

    Time frame: Up to 125 weeks

  5. Best Overall Response (BRR)

    The best overall response will be the best response recorded from the start of the treatment until disease progression/recurrence.

    Time frame: Up to 125 weeks

  6. Best Complete response (CR) rate

    The best CR rate will be calculated as the proportion of participants who obtained a CR at any point during study treatment.

    Time frame: Up to 125 weeks

  7. Overall response rate (ORR) after 3 cycles of zanubrutinib + BR

    ORR is defined as the proportion of participants who experienced complete response (CR) or partial response (PR) after 3 cycles of zanubrutinib + BR

    Time frame: Up to 125 weeks

  8. Complete response rate (CRR) after 3 cycles of zanubrutinib + BR

    CRR is defined as the proportion of participants who experienced complete response (CR) after 3 cycles of zanubrutinib + BR

    Time frame: Up to 125 weeks

  9. Partial response rate (PRR) after 3 cycles of zanubrutinib + BR

    PRR is defined as the proportion of participants who experienced partial response (PR) after 3 cycles of zanubrutinib + BR

    Time frame: Up to 125 weeks

  10. Overall response rate (ORR) after 6 cycles of BRAZAN induction

    ORR is defined as the proportion of participants who experienced complete response (CR) or partial response (PR) after 6 cycles of BRAZAN induction

    Time frame: Up to 125 weeks

  11. Complete response rate (CRR) after 6 cycles of BRAZAN induction

    CRR is defined as the proportion of participants who experienced complete response (CR) after 6 cycles of BRAZAN induction

    Time frame: Up to 125 weeks

  12. Partial response rate (PRR) after 6 cycles of BRAZAN induction

    PRR is defined as the proportion of participants who experienced partial response (PR) after 6 cycles of BRAZAN induction

    Time frame: Up to 125 weeks

  13. Overall response rate (ORR) after the entire treatment course

    ORR is defined as the proportion of participants who experienced complete response (CR) or partial response (PR) after the entire treatment course

    Time frame: Up to 125 weeks

  14. Complete response rate (CRR) after the entire treatment course

    CRR is defined as the proportion of participants who experienced complete response (CR) after the entire treatment course

    Time frame: Up to 125 weeks

  15. Partial response rate (PRR) after the entire treatment course

    PRR is defined as the proportion of participants who experienced partial response (PR) after the entire treatment course

    Time frame: Up to 125 weeks

  16. Overall response rate (ORR) after the entire treatment course in doublet arm

    ORR is defined as the proportion of participants who experienced complete response (CR) or partial response (PR) after the entire treatment course in doublet arm.

    Time frame: Up to 125 weeks

  17. Complete response rate (CRR) after the entire treatment course in doublet arm

    CRR is defined as the proportion of participants who experienced complete response (CR) after the entire treatment course in doublet arm.

    Time frame: Up to 125 weeks

  18. Partial response rate (PRR) after the entire treatment course in doublet arm

    PRR is defined as the proportion of participants who experienced partial response (PR) after the entire treatment course in doublet arm.

    Time frame: Up to 125 weeks

  19. Overall response rate (ORR) after the entire treatment course in triplet arm

    ORR is defined as the proportion of participants who experienced complete response (CR) or partial response (PR) after the entire treatment course in triplet arm.

    Time frame: Up to 125 weeks

  20. Complete response rate (CRR) after the entire treatment course in triplet arm

    CRR is defined as the proportion of participants who experienced complete response (CR) after the entire treatment course in triplet arm.

    Time frame: Up to 125 weeks

  21. Partial response rate (PRR) after the entire treatment course in triplet arm

    PRR is defined as the proportion of participants who experienced partial response (PR) after the entire treatment course in triplet arm.

    Time frame: Up to 125 weeks

  22. Duration of response (DOR)

    The duration of response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  23. Duration of complete response (DOCR)

    The duration of CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  24. Duration of response (DOR) in doublet arm

    The duration of response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  25. Duration of complete response (DOCR) in doublet arm

    The duration of CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  26. Duration of response (DOR) in triplet arm

    The duration of response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  27. Median Duration of complete response (DOCR) in triplet arm

    The duration of CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented, or death due to any cause. Participants without events reported are censored at the last disease evaluation.

    Time frame: Up to 10 years

  28. Progression free survival (PFS)

    Progression-Free Survival is defined as the time from treatment start to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

    Time frame: Up to 10 years

  29. Progression free survival (PFS) in doublet arm

    Progression-Free Survival is defined as the time from treatment start to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

    Time frame: Up to 10 years

  30. Progression free survival (PFS) in triplet arm

    Progression-Free Survival is defined as the time from treatment start to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.

    Time frame: Up to 10 years

  31. Overall Survival (OS)

    Overall Survival is defined as the time from treatment start to death due to any cause, or censored at date last known alive.

    Time frame: Up to 10 years

  32. Overall Survival (OS) in doublet arm

    Overall Survival is defined as the time from treatment start to death due to any cause, or censored at date last known alive.

    Time frame: Up to 10 years

  33. Overall Survival (OS) in triplet arm

    Overall Survival is defined as the time from treatment start to death due to any cause, or censored at date last known alive.

    Time frame: Up to 10 years

  34. Rate of peripheral blood (PB) MRD-negativity after 6 cycles of induction therapy

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  35. Rate of peripheral blood (PB) MRD-negativity after 12 cycles of maintenance treatment in doublet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  36. Rate of peripheral blood (PB) MRD-negativity after 12 cycles of maintenance treatment in triplet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  37. Rate of peripheral blood (PB) MRD-negativity after 24 cycles of maintenance treatment in doublet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  38. Rate of peripheral blood (PB) MRD-negativity after 24 cycles of maintenance treatment in triplet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  39. Best rate of peripheral blood (PB) MRD-negativity after up to 24 cycles of maintenance treatment in doublet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

  40. Best rate of peripheral blood (PB) MRD-negativity after up to 24 cycles of maintenance treatment in triplet arm

    Peripheral blood MRD will be measured by the clonoSEQ assay.

    Time frame: Up to 125 weeks

07

Study locations

4 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: innovation@dfci.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2029, 54 months after the start.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 54 months is below that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
Apr 22, 2025
Primary completionEst.
Nov 1, 2029
CompletionEst.
Nov 1, 2039
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06854003
Lead sponsor
Christine Ryan
Collaborators
BeiGene
Responsible party
Christine Ryan (Sponsor Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Mar 3, 2025
Start date
Apr 22, 2025
Primary completion
Nov 1, 2029 (estimated)
Completion
Nov 1, 2039 (estimated)
Last update
Feb 20, 2026

Study contacts

Dana-Farber Cancer Institute Clinical Trials
Contact
DFCILymphomaResearchNurses@partners.org
877-DF-TRIAL (877-338-7425)
Clare Phinney
Contact
clare_phinney@dfci.harvard.edu
Christine Ryan, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Zanubrutinib

Start the discussion